Alphagan is a medicine used to treat the symptoms of Elevated Intraocular Pressure and Ocular Redness. Alphagan may be used alone or with other medications.
Alphagan belongs to a class of drugs called Antiglaucoma, Alpha Agonists.
It is not known if Alphagan is safe and effective in children younger than 2 years of age.
Alphagan 0.2%
| Package | bottle | Total price | Save | Order |
|---|---|---|---|---|
| 5ml × 1 Bottles | $46.85 | $46.85 | - | Add to cart |
| 5ml × 2 Bottles | $39.18 | $78.35 | $15.34 | Add to cart |
| 5ml × 4 Bottles | $35.34 | $141.37 | $46.04 | Add to cart |
| 5ml × 8 Bottles | $33.43 | $267.42 Free Trackable Delivery | $107.36 | Add to cart |
| 5ml × 16 Bottles | $32.47 | $519.50 Free Trackable Delivery | $230.08 | Add to cart |
Your order will be packed safely and securely and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has the size and the look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm), and it does not disclose its contents
Drug uses
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Overdosage
Very limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving ALPHAGAN® P (brimonidine tartrate) as part of medical treatment of congenital glaucoma or by accidental oral ingestion. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.
Storage
Store at 15° - 25°C (59° - 77°F).
Safety information
Warnings
Potentiation of Vascular Insufficiency ALPHAGAN® P (brimonidine tartrate) may potentiate syndromes associated with vascular insufficiency. ALPHAGAN® P (brimonidine tartrate) should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Disclaimer
The information on this page is not intended to be a substitute for professional medical advice. Do not use this information to diagnose or treat your problem without consulting your doctor.
Side effects
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Adverse reactions occurring in approximately 10-20%of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5-9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
Adverse reactions occurring in approximately 1-4% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: abnormal taste, allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.
The following reactions were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.
Viagra Oral Jelly - a new formula of the drug Viagra. Sildenafil - 100 mg. It is prescribed for men with a weak potentiality. Helps to recover libido and to improve sexual activity. Accelerates process of excitement of reproductive system. It makes erection brighter. Considerably increases duration of sexual intercourse. Besides, drug has various pleasant tastes, it is convenient to carry in a pocket or in a purse. Hurry to try it!
Cialis is a latest medicine for treatment of disturbances of erection at men. Cialis feature is its high-speed performance (30 minutes) and a long-term effect (up to 36 hours). In this regard you can choose the moment which is most suitable for sexual intercourse, having accepted a drug in advance. It is possible to take Cialis in the morning and to be ready even next day. Active ingredient - Tadalafil, the recommended dosage - 20 mg.
Brand Levitra – a drug from Bayer, with a basic chemical called Vardenafil, is an improved remedy for treating erectile difficulties. Operates approximately within 6-8 hours, so a man may be ready to perform sexually the whole night.
Brand Cialis improves erection and helps to achieve a successful sexual intercourse. It is the original medication, intended for use in adult men, who have problems with achieving and maintaining an erection. The pills start acting in 30 to 60 minutes. You can benefit from their effects for up to 36 hours. Therefore, you can take the pills on Saturday evening and enjoy a wonderful weekend, full of sex and pleasant emotions both for you and your partner. The active substance is Tadalafil.
Doxazosin is used for treating hypertension (high blood pressure) and enlarged prostate. The drug increases the blood flow by expanding the veins and arteries. It also relaxes the muscles of the prostate and the neck of urinary bladder, making it easier to urinate.
The medicine is a potent agent that reduces intraocular pressure, belongs to the group of synthetic prostanoid. The mechanism of action, through which Lumigan reduces intraocular pressure in humans results in increasing of the outflow of intraocular fluid through the trabecular mesh and in increasing of the outflow from the uveoscleral eye. The decrease in intraocular pressure begins around 4 hours after the first application. The maximum effect is achieved within approximately 8-12 hours. The effect lasts at least 24 hours.
